Map the system. Preserve the evidence. Test the handoff.
Source-backed reporting and analysis connected to the companies, capabilities, authorities, and operating domains it affects.
FDA good laboratory practice rules give the study director overall study control while requiring an independent quality assurance unit for each study. Laboratory systems should preserve both roles without letting workflow convenience erase the review boundary.
For drug CGMP laboratory records within its scope, 21 CFR 211.194 connects the sample, method, raw data, calculations, result, performer, and second-person review. A final result in a LIMS is not the complete record when the source observations and review path cannot be reconstructed.
The regulator's publication page preserves its GxP guidance while noting that OECD Advisory Document No. 22 takes precedence for GLP data integrity.
The official informatics record spans sample operations, experiment records, procedure execution, scientific-data management, analytics, and specialty workflows on one portfolio.
The current product record combines LIMS, ELN, and LES positioning with instrument and analytical-data connections, creating a useful system-boundary test for buyers.
The product page documents the current chromatography data-system family while buyers still need version-specific evidence for instruments, processing, controls, interfaces, migration, and retained records.
The official platform record centers ingest, engineering, harmonization, context, data products, and application access rather than replacing the LIMS, ELN, CDS, or instrument that creates an operational record.
